Table 2.
Multiple Linear Regression Analysis of Factors Associated with Total FIM Score at Discharge in All Patients.
| Variable | B | SE | 95% CI | p Value |
|---|---|---|---|---|
| Age, years | −0.12 | 0.09 | −0.29 to 0.06 | 0.193 |
| Sex: female | 0.90 | 2.08 | −3.20 to 4.99 | 0.667 |
| BMI, kg/m2 | 0.45 | 0.27 | −0.08 to 0.97 | 0.094 |
| Charlson Comorbidity Index | −0.36 | 0.70 | −1.74 to 1.02 | 0.611 |
| Stroke type: hemorrhagic stroke | −2.25 | 2.45 | −7.07 to 2.58 | 0.360 |
| Pre-stroke mRS: 3-4 | −9.84 | 2.72 | −15.20 to −4.49 | <0.001 |
| NIHSS at admission | −0.48 | 0.15 | −0.77 to −0.20 | 0.001 |
| Serum albumin at admission, g/dL | 1.94 | 2.00 | −1.99 to 5.87 | 0.332 |
| Admission motor FIM score | 0.55 | 0.07 | 0.42 to 0.68 | <0.001 |
| Admission cognitive FIM score | 1.58 | 0.14 | 1.30 to 1.86 | <0.001 |
| Pre-admission polypharmacy | −4.70 | 2.22 | −9.07 to −0.33 | 0.035 |
Multivariable linear regression analysis was performed with total FIM score at discharge as the dependent variable. All variables were entered simultaneously using the forced-entry method. B indicates the unstandardized regression coefficient. Pre-admission polypharmacy was defined as the use of five or more regular pre-admission medications. The reference categories were male sex, ischemic stroke, pre-stroke mRS 0-2, and non-polypharmacy.
BMI: body mass index; CI: confidence interval; FIM: Functional Independence Measure; mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale; SE: standard error.